NEW YORK, Feb 1 – Large Scale Biology's fourth quarter revenues decreased slightly from a year ago, the company reported Thursday. LSBC attributed the drop in revenue, from $5.9 to $5.7 million, primarily to decreased development funding from Dow Chemical and Dow AgroSciences.

Higher R&D costs in the fourth quarter of 2000 compounded the drop in contract funding from Dow, the company said. Compared to the year-ago fourth quarter, R&D expenditures were up 87 percent to $4.7 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.